Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:7/7/2009

ng public health crisis.

Contract manufacturing services:

We recently completed our $22 million manufacturing facility. During the next 3 months, it will be validated for clinical supplies and readied for contract manufacturing. This facility was built to manufacture Multikine for the Phase III trial and sale thereafter. Due to the unique requirements for Multikine, we have developed over the last 10 years a cold fill at this facility which is not available for contract manufacturing anywhere else. This means that we can fill our Multikine into vials in a completely sterile manner not only at room temperature, as everyone else does, but also at 4 degrees Centigrade. For Multikine, this is a critical step since long exposure to room temperature not only "kills" the biological activity of the investigational product, but may also alter the ratios of the biologically active components and therefore change Multikine. Similar needs exist for every other biologic, including stem cell-derived products and biosimilars. Our 4 degree Centigrade cold aseptic fill will be offered to the industry as a contract service. I leave you with one simple thought: how would your life be affected if you did not have a refrigerator or freezer? We believe that the 4 degree Centigrade cold aseptic fill has the same kind of impact on the pharmaceutical/biotechnology drug industry.

Multikine cancer therapy:

We believe that the most critical step the company can take is to enter the pivotal Phase III clinical trial to support marketing applications for Multikine. In published studies, Multikine has been shown to be non-toxic, to increase survival by 33%, and to eliminate the tumor in 12% of the patients after only a 3-week treatment. The recent success of Dendreon with its prostate cancer vaccine has shown that it is possible to stimulate the immune system of cancer patients to increase survival. Dendr
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Announces 2008 Financial Results
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DALLAS , September 29, 2014 /PRNewswire/ ... market research report "Epigenetics Market by Product (Modifying ... Consumables, Kit, Bisulphite Conversion Kit, Reagents), by ... User - Global Forecast to 2019", published ... the major drivers, restraints, opportunities, current market ...
(Date:9/29/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, is ... to Chairman of the Board of Directors of ... continue to serve as a Director on the Board ... "We are very pleased to have ...
(Date:9/29/2014)... , Sept. 29, 2014  Perrigo Company plc ... that it has transferred a portfolio of preclinical ... 2013 acquisition of Elan Corporation plc, to drug ... of the agreement, Perrigo will receive an upfront ... and royalties on any future sales derived from ...
(Date:9/28/2014)... Boston, Mass. (PRWEB) September 29, 2014 ... delivers integrated cold chain management solutions for highly ... Brian Brazill, will present the company’s Advantage Transport ... Chain GDP & Temperature Management Logistics Global Forum ... will explain and demonstrate the company’s lab software ...
Breaking Biology Technology:Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4SQI Diagnostics Announces New Chairman of Board of Directors 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3
... PARSIPPANY, N.J., Sept. 1, 2011 New data, published ... the long-term safety and tolerability of FIRMAGON ® ... cancer when used over three years.(1) The new study ... III study (CS21) in which FIRMAGON ® was ...
... BRUSSELS, September 1, 2011 The current ... successful research into blood-related diseases must ensure the safety ... This was a key message of a ... by the European Parliament and attended by doctors, researchers, ...
... September 1, 2011 The medical imaging ... has secured an order for their magnetic resonance imaging ... The software will be used in clinical practice to ... The software, SyMRI Diagnostics, includes tools to automatically ...
Cached Biology Technology:New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 2New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 3New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 4New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 5New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 6Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3
(Date:9/29/2014)... President Juan Manuel Santos has presented Dr. Cristin ... Society, with the prestigious Order of San Carlos. ... citizens, foreign civilians and military officers who have ... the field of international relations. , An international ... Samper was invited to the Colombian Residence in ...
(Date:9/29/2014)... deemed inaccessible or esoteric. Yet in the modern world, ... daily lives and a decisive role in the discovery ... scenes. , UC Santa Barbara,s Paul Atzberger, a professor ... of mechanical engineering, often works in areas where science ... in the Proceedings of the National Academy of ...
(Date:9/29/2014)... a real-time feedback system together with a human energy ... reduction of 37% in energy consumption when compared to ... equivalent to a reduction of 713.71 kg of CO ... another eight halls, exposed only to the real-time feedback ... 3.5% reduction in energy consumption. , Student,s energy-use behaviour ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4
... for the planet,s gravest health threats is hatched by ... new report sets out a 10-point plan for this ... flu. Ministers of health and agriculture will formulate ... the threat of avian flu and other emerging infectious ...
... Integrates with,Citrix Password Manager Single-Sign On Solution ... Oct. 22 Fujitsu Computer Products of,America, ... products including,hard disk drives, peripherals and biometric ... has been verified as Citrix,Ready(TM). The PalmSecure ...
... The leading cause of death in all cancer patients ... a form of treatment in which chemicals are used to ... biochemists that focuses on cancer cells reports that ingesting apigenin ... fruit improves cancer cells, response to chemotherapy. ...
Cached Biology News:Avian flu threat: New approach needed 2Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 2Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 3Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 4How eating fruit and vegetables can improve cancer patients' response to chemotherapy 2
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
... Kit with CyScribe GFX Purification Kit, ... purification of Cy3- and Cy5-labeled cDNA.Optimized ... cDNA labeling and purification.Flexible and optimized ... labeling reactions with either Cy3- or ...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Biology Products: